For fully vaccinated, immunity against SARS-CoV-2 wanes over time
Oct 29, 2021
The researchers found that among persons aged 60 years or older, the rate of infection was higher for those fully vaccinated in January 2021 (when they were first eligible) versus those fully vaccinated...
Aging services leaders issue urgent plea for federal plan to end ‘national nightmare’ of COVID-19
By
Lois A. Bowers
Aug 06, 2020
A federal plan is needed to end the “national nightmare” of the pandemic, the leaders of six national organizations representing aging services providers told the president, vice president and leaders...
Many healthcare employers not reporting COVID-19 worker deaths: analysis
By
Amy Novotney
Dec 02, 2020
Some healthcare employers — including a number of long-term care facilities — have been choosing not to report healthcare worker deaths to occupational safety officials amid the pandemic, according...
No elevated risk for stroke seen after COVID-19 bivalent vaccine receipt
Mar 20, 2024
No evidence was seen for an increased risk for stroke in one- to 21-day or 22- to 42-day windows compared with a 43- to 90-day window after the vaccine.
It’s a bit early for a victory parade
By
John O'Connor
May 21, 2020
The stock market spiked notably Monday, following news that a COVID-19 vaccine candidate has shown encouraging trial results. But before you load up on Moderna stock, it might be helpful to keep a couple...
Bipartisan lawmakers propose new $908B COVID-19 relief bill that includes liability protections, support...
By
Amy Novotney
Dec 02, 2020
A group of bipartisan House and Senate lawmakers on Tuesday introduced a $908 billion COVID-19 relief proposal that includes liability protections, support for small businesses and at least some federal...
Most neurologic symptoms persist for COVID-19 long haulers
Jun 02, 2022
SARS-CoV-2 vaccination appears to have no positive or negative impact on cognitive function or fatigue.
Bivalent mRNA-1273.214 elicits better response against omicron
Sep 27, 2022
A booster dose of mRNA-1273.214 elicits more neutralizing antibodies against omicron compared with mRNA-1273, the original Moderna vaccine, with no new safety concerns.
FDA approves Pfizer pill as first at-home COVID-19 treatment
Dec 22, 2021
A recent trial showed that Paxlovid cut the odds for hospitalization and death by nearly 90 percent in high-risk people.
Risk for progression to severe COVID-19 lower with nirmatrelvir + ritonavir
Mar 01, 2022
Treatment of symptomatic COVID-19 with nirmatrelvir plus ritonavir was linked to an 89% lower risk for progression versus placebo.